1. Home
  2. FEMY vs CVM Comparison

FEMY vs CVM Comparison

Compare FEMY & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Femasys Inc.

FEMY

Femasys Inc.

HOLD

Current Price

$0.47

Market Cap

23.2M

Sector

Health Care

ML Signal

HOLD

Logo Cel-Sci Corporation

CVM

Cel-Sci Corporation

HOLD

Current Price

$1.48

Market Cap

19.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FEMY
CVM
Founded
2004
1983
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.2M
19.3M
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
FEMY
CVM
Price
$0.47
$1.48
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$5.50
N/A
AVG Volume (30 Days)
363.1K
180.1K
Earning Date
05-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
44.71
N/A
EPS
N/A
N/A
Revenue
$2,293,313.00
$264,033.00
Revenue This Year
$105.16
N/A
Revenue Next Year
$200.23
N/A
P/E Ratio
N/A
N/A
Revenue Growth
40.77
65.45
52 Week Low
$0.31
$0.23
52 Week High
$1.16
$13.48

Technical Indicators

Market Signals
Indicator
FEMY
CVM
Relative Strength Index (RSI) 61.01 23.95
Support Level $0.33 N/A
Resistance Level $0.58 $4.84
Average True Range (ATR) 0.03 0.33
MACD 0.01 -0.24
Stochastic Oscillator 94.53 1.00

Price Performance

Historical Comparison
FEMY
CVM

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

About CVM Cel-Sci Corporation

CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.

Share on Social Networks: